200 Participants Needed

Exercise Program + Fitbit Monitoring for Prostate Cancer

CJ
Overseen ByChristopher J Logothetis
Age: 18+
Sex: Male
Trial Phase: Phase 2
Sponsor: M.D. Anderson Cancer Center
Must be taking: GnRH agonists/antagonists
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores whether an exercise program, combined with Fitbit monitoring, can help manage metabolic syndrome and heart health in men with prostate cancer that has spread or returned and doesn't respond to treatment. Participants will either receive general exercise guidance or join supervised exercise sessions, both while wearing a Fitbit. The trial targets those with prostate cancer who are currently on hormone therapy and can still engage in physical activities despite their condition. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to important advancements in prostate cancer care.

Do I have to stop taking my current medications for the trial?

The trial does not specify if you need to stop taking your current medications. However, it allows the use of certain prostate cancer treatments like GnRH agonists/antagonists, abiraterone, enzalutamide, bisphosphonates, or RANK-ligand inhibitors. It's best to discuss your specific medications with the trial team.

What prior data suggests that this exercise program and Fitbit monitoring are safe for prostate cancer patients?

Research shows that exercise is a safe and promising way to manage side effects of prostate cancer and its treatments. Studies have found that both aerobic and resistance exercises can enhance the quality of life and fitness for prostate cancer patients, with no major harmful effects reported. This indicates that patients generally tolerate exercise well.

Studies have confirmed that the Fitbit effectively tracks physical activity in men with prostate cancer. Although some users may encounter minor issues, the Fitbit remains a reliable and acceptable tool for monitoring exercise.

The current trial is in Phase 2, so researchers are still gathering detailed information on the exercise program's effectiveness and safety. However, previous studies on similar programs suggest these treatments are safe for participants.12345

Why are researchers excited about this trial?

Researchers are excited about this trial because it explores how exercise, combined with Fitbit monitoring, could benefit prostate cancer patients. Unlike standard treatments like surgery, radiation, or hormone therapy, this approach focuses on integrating regular physical activity into patients' routines. Group I encourages patients to exercise independently using a general education packet, while Group II involves both supervised and self-directed sessions. The use of Fitbits offers real-time monitoring and feedback, potentially helping patients stay motivated and consistent with their exercise. Researchers hope this method could enhance patient outcomes by improving fitness and quality of life without the side effects of traditional treatments.

What evidence suggests that this exercise program and Fitbit monitoring could be effective for managing metabolic syndrome and cardiovascular disease risk in prostate cancer patients?

Research shows that exercise greatly benefits men with prostate cancer. It improves overall quality of life, enhances general health, and sharpens mental acuity. Studies have found that exercise can lessen cancer severity and might slow tumor growth and spread. Additionally, exercise links to better heart health and improved sexual function in prostate cancer patients. In this trial, participants in both groups will use a Fitbit to track activity, motivating more regular exercise and potentially boosting these benefits.16789

Who Is on the Research Team?

CJ

Christopher Logothetis

Principal Investigator

M.D. Anderson Cancer Center

Are You a Good Fit for This Trial?

This trial is for men with metastatic or recurrent prostate cancer that's resistant to treatment and are on hormone therapy. They should be able to perform physical activities, have stable disease, and not be undergoing certain other treatments. Participants need a smartphone and must speak English.

Inclusion Criteria

My platelet count is at least 75,000 without transfusions in the last 3 months.
Able to speak and comprehend English
My cancer has spread, as shown by scans, or it came back after surgery or radiation.
See 11 more

Exclusion Criteria

I have bone pain due to cancer spread.
I do not have serious heart conditions that would make exercise unsafe.
I haven't had chemotherapy in the last 28 days.
See 10 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants engage in a 16-week exercise program with continuous Fitbit monitoring to manage metabolic syndrome and cardiovascular risk

16 weeks
Regular exercise sessions, Fitbit monitoring daily

Follow-up

Participants are monitored for cardiovascular fitness and metabolic syndrome severity post-intervention

12 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Exercise Intervention
  • FitBit
Trial Overview The study tests if an exercise program along with continuous Fitbit monitoring can manage metabolic syndrome and reduce heart disease risk in prostate cancer patients on hormone therapy. It includes quality-of-life assessments, questionnaires, and educational components.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: Group II (exercise program FitBit)Experimental Treatment4 Interventions
Group II: Group I (education exercise packet, FitBit)Active Control4 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

M.D. Anderson Cancer Center

Lead Sponsor

Trials
3,107
Recruited
1,813,000+

National Cancer Institute (NCI)

Collaborator

Trials
14,080
Recruited
41,180,000+

Published Research Related to This Trial

The 'Football Club (FC) Prostate' study is a randomized trial involving 80 men undergoing androgen deprivation therapy (ADT) for advanced prostate cancer, aiming to evaluate the effects of soccer training on various health outcomes over a 12-week period.
The primary focus is on changes in lean body mass, with secondary outcomes including cardiovascular function and patient-reported quality of life, potentially demonstrating that soccer training can be a safe and effective rehabilitation strategy for men receiving ADT.
Effects of recreational soccer in men with prostate cancer undergoing androgen deprivation therapy: study protocol for the 'FC Prostate' randomized controlled trial.Uth, J., Schmidt, JF., Christensen, JF., et al.[2021]
A six-month supervised exercise program significantly improved physical performance, muscular strength, and quality of life in 27 prostate cancer patients undergoing androgen deprivation therapy.
The exercise program was well tolerated and highlighted the need for screening cardio-metabolic risk factors in these patients, as they initially presented with an unfavorable cardio-metabolic profile.
Effects of a six-month supervised physical exercise program on physical and cardio-metabolic profile and quality of life in patients with prostate cancer on androgen deprivation therapy: a pilot and feasibility study.Zabegalina, NS., Henderickx, MMEL., Lamotte, V., et al.[2022]
This phase III randomized controlled trial involves 866 participants with metastatic castrate-resistant prostate cancer (mCRPC) to assess whether supervised high-intensity aerobic and resistance exercise can improve overall survival compared to self-directed exercise.
The study will also explore the relationship between exercise and various health factors, such as immune function and metabolic biomarkers, which may help understand how exercise impacts survival outcomes in mCRPC patients.
Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol.Newton, RU., Kenfield, SA., Hart, NH., et al.[2022]

Citations

Comparing aerobic and resistance exercise emphasis ...This study aimed to determine the feasibility of an aerobic-emphasised (AE) versus a resistance-emphasised (RE) exercise intervention in men with prostate ...
The Effect of Resistance and/or Aerobic Training on Quality of ...The results show that combining strength and aerobic exercise significantly improves quality of life, especially in general health, mental clarity, and sexual ...
Effects of exercise training on prostate cancerExercise has emerged as a promising strategy, with evidence suggesting its efficacy in reducing cancer severity, inhibiting tumor progression and metastasis.
Exercise and Psychosexual Education to Improve Sexual ...In this randomized clinical trial including 112 patients with prostate cancer, exercise improved erectile function compared with usual care.
Exercise medicine in men with prostate cancerExercise intervention studies in men with prostate cancer have shown well documented improvements in objective and self-reported outcomes ...
A comparison of aerobic- and resistance-emphasised ...Most exercise studies in men with prostate cancer have utilised single exercise groups that combine resistance and aerobic exercise [[21], [22], ...
The effects of exercise on body composition of prostate cancer ...This review suggested that exercise ameliorated the ADT-related side effects on body composition among prostate cancer patients, with longer and ...
8.pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov/40540036/
Comparing aerobic and resistance exercise emphasis ...This study aimed to determine the feasibility of an aerobic-emphasised (AE) versus a resistance-emphasised (RE) exercise intervention in men with prostate ...
The Effect of Resistance and/or Aerobic Training on Quality ...Conclusions: RT and combined RT/AT significantly improve QoL, fitness, and body composition in PC patients, with no detectable effect on PSA or lipid levels.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security